|
1
|
Rieder F and Fiocchi C: Intestinal
fibrosis in inflammatory bowel disease-current knowledge and future
perspectives. J Crohns Colitis. 2:279–290. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rieder F and Fiocchi C: Mechanisms of
tissue remodeling in inflammatory bowel disease. Dig Dis.
31:186–193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Limketkai BN and Bayless TM: Editorial:
can stenosis in ileal Crohn’s disease be prevented by current
therapy? Am J Gastroenterol. 108:1755–1756. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Latella G, Sferra R, Speca S, Vetuschi A
and Gaudio E: Can we prevent, reduce or reverse intestinal fibrosis
in IBD? Eur Rev Med Pharmacol Sci. 17:1283–1304. 2013.PubMed/NCBI
|
|
5
|
McKaig BC, McWilliams D, Watson SA and
Mahida YR: Expression and regulation of tissue inhibitor of
metal-loproteinase-1 and matrix metalloproteinases by intestinal
myofibroblasts in inflammatory bowel disease. Am J Pathol.
162:1355–1360. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kruidenier L, MacDonald TT, Collins JE,
Pender SL and Sanderson IR: Myofibroblast matrix metalloproteinases
activate the neutrophil chemoattractant CXCL7 from intestinal
epithelial cells. Gastroenterology. 130:127–136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tao X and Lipsky PE: The Chinese
anti-inflammatory and immunosuppressive herbal remedy Tripterygium
wilfordii Hook F. Rheum Dis Clin North Am. 26:29–50. viii2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma J, Dey M, Yang H, et al:
Anti-inflammatory and immu-nosuppressive compounds from
Tripterygium wilfordii. Phytochemistry. 68:1172–1178. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ji SM, Wang QW, Chen JS, Sha GZ, Liu ZH
and Li LS: Clinical trial of Tripterygium Wilfordii Hook F. in
human kidney transplantation in China. Transplant Proc.
38:1274–1279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan XP, He XS, Wang CX, Liu LS and Fu Q:
Triptolide attenuates renal interstitial fibrosis in rats with
unilateral ureteral obstruction. Nephrology (Carlton). 16:200–210.
2011. View Article : Google Scholar
|
|
11
|
Chong LW, Hsu YC, Chiu YT, Yang KC and
Huang YT: Antifibrotic effects of triptolide on hepatic stellate
cells and dimethylnitrosamine-intoxicated rats. Phytother Res.
25:990–999. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krishna G, Liu K, Shigemitsu H, Gao M,
Raffin TA and Rosen GD: PG490-88, a derivative of triptolide,
blocks bleomycin-induced lung fibrosis. Am J Pathol. 158:997–1004.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tao QS, Ren JA and Li JS: Triptolide
suppresses IL-1beta-induced chemokine and stromelysin-1 gene
expression in human colonic subepithelial myofibroblasts. Acta
Pharmacol Sin. 28:81–88. 2007.
|
|
14
|
Ren J, Tao Q, Wang X, Wang Z and Li J:
Efficacy of T2 in active Crohn’s disease: a prospective study
report. Dig Dis Sci. 52:1790–1797. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li G, Ren J, Wang G, et al: T2 enhances in
situ level of Foxp3 regulatory cells and modulates inflammatory
cytokines in Crohn’s disease. Int Immunopharmacol. 18:244–248.
2014. View Article : Google Scholar
|
|
16
|
Yamada Y, Marshall S, Specian RD and
Grisham MB: A comparative analysis of two models of colitis in
rats. Gastroenterology. 102:1524–1534. 1992.PubMed/NCBI
|
|
17
|
Hogaboam CM, Chensue SW, Steinhauser ML,
et al: Alteration of the cytokine phenotype in an experimental lung
granuloma model by inhibiting nitric oxide. J Immunol.
159:5585–5593. 1997.
|
|
18
|
Mahida YR, Beltinger J, Makh S, et al:
Adult human colonic subepithelial myofibroblasts express
extracellular matrix proteins and cyclooxygenase-1 and -2. Am J
Physiol. 273:G1341–1348. 1997.
|
|
19
|
Roholl PJ, Elbers HR, Prinsen I, Claessens
JA and van Unnik JA: Distribution of actin isoforms in sarcomas: an
immunohistochemical study. Hum Pathol. 21:1269–1274. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iwanaga K, Murata T, Hori M and Ozaki H:
Isolation and characterization of bovine intestinal subepithelial
myofibroblasts. J Pharmacol Sci. 112:98–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paulin D and Li Z: Desmin: a major
intermediate filament protein essential for the structural
integrity and function of muscle. Exp Cell Res. 301:1–7. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu MY, Lu YM, Ou YX, Zhang HZ and Chen
WX: Dynamic progress of 2,4,6-trinitrobenzene sulfonic acid induced
chronic colitis and fibrosis in rat model. J Dig Dis. 13:421–429.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lawrance IC, Wu F, Leite AZ, et al: A
murine model of chronic inflammation-induced intestinal fibrosis
down-regulated by antisense NF-kappaB. Gastroenterology.
125:1750–1761. 2003. View Article : Google Scholar
|
|
24
|
Rieder F, Brenmoehl J, Leeb S, Schölmerich
J and Rogler G: Wound healing and fibrosis in intestinal disease.
Gut. 56:130–139. 2007. View Article : Google Scholar
|
|
25
|
Graham MF: Pathogenesis of intestinal
strictures in Crohn’s disease-an update. Inflamm Bowel Dis.
1:220–227. 1995.PubMed/NCBI
|
|
26
|
Fiocchi C: Intestinal inflammation: a
complex interplay of immune and nonimmune cell interactions. Am J
Physiol. 273:G769–775. 1997.PubMed/NCBI
|
|
27
|
Pucilowska JB, Williams KL and Lund PK:
Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular
mediators and animal models. Am J Physiol Gastrointest Liver
Physiol. 279:G653–659. 2000.PubMed/NCBI
|
|
28
|
Burke JP, Mulsow JJ, O’Keane C, Docherty
NG, Watson RW and O’Connell PR: Fibrogenesis in Crohn’s disease. Am
J Gastroenterol. 102:439–448. 2007. View Article : Google Scholar
|
|
29
|
Luna J, Masamunt MC, Lawrance IC and Sans
M: Mesenchymal cell proliferation and programmed cell death: key
players in fibrogenesis and new targets for therapeutic
intervention. Am J Physiol Gastrointest Liver Physiol.
300:G703–708. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pelletier AL, Kalisazan B, Wienckiewicz J,
Bouarioua N and Soulé JC: Infliximab treatment for symptomatic
Crohn’s disease strictures. Aliment Pharmacol Ther. 29:279–285.
2009. View Article : Google Scholar
|
|
31
|
Froehlich F, Juillerat P, Mottet C, et al:
Fibrostenotic Crohn’s disease. Digestion. 76:113–115. 2007.
View Article : Google Scholar
|
|
32
|
Dietz DW, Laureti S, Strong SA, et al:
Safety and longterm efficacy of strictureplasty in 314 patients
with obstructing small bowel Crohn’s disease. J Am Coll Surg.
192:330–338. 2001. View Article : Google Scholar
|
|
33
|
Fearnhead NS, Chowdhury R, Box B, George
BD, Jewell DP and Mortensen NJ: Long-term follow-up of
strictureplasty for Crohn’s disease. Br J Surg. 93:475–482. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen M, et al: Triptolide inhibits TGF-β1
induced proliferation and migration of rat airway smooth muscle
cells by suppressing NF-κB but not ERK1/2. Immunology. 2014.
View Article : Google Scholar
|
|
35
|
Hoyle GW, et al: Identification of
triptolide, a natural diterpenoid compound, as an inhibitor of lung
inflammation. Am J Physiol Lung Mol Physiol. 298:L830–L836. 2010.
View Article : Google Scholar
|
|
36
|
Qiu D, Zhao G, Aoki Y, et al:
Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2
expression at the level of purine-box/nuclear factor of activated
T-cells and NF-kappaB transcriptional activation. J Biol Chem.
274:13443–13450. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Choi YJ, Kim TG, Kim YH, et al:
Immunosuppressant PG490 (triptolide) induces apoptosis through the
activation of caspase-3 and down-regulation of XIAP in U937 cells.
Biochem Pharmacol. 66:273–280. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang Y, Liu Z, Tolosa E, Yang J and Li L:
Triptolide induces apoptotic death of T lymphocyte.
Immunopharmacology. 40:139–149. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu Q, Chen T, Chen G, et al:
Immunosuppressant triptolide inhibits dendritic cell-mediated
chemoattraction of neutrophils and T cells through inhibiting Stat3
phosphorylation and NF-kappaB activation. Biochem Biophys Res
Commun. 345:1122–1130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rieder F, Zimmermann EM, Remzi FH and
Sandborn WJ: Crohn’s disease complicated by strictures: a
systematic review. Gut. 62:1072–1084. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Matsuno K, Adachi Y, Yamamoto H, et al:
The expression of matrix metalloproteinase matrilysin indicates the
degree of inflammation in ulcerative colitis. J Gastroenterol.
38:348–354. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vaalamo M, Karjalainen-Lindsberg ML,
Puolakkainen P, Kere J and Saarialho-Kere U: Distinct expression
profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13),
macrophage metalloelastase (MMP-12) and tissue inhibitor of
metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J
Pathol. 152:1005–1014. 1998.PubMed/NCBI
|
|
43
|
Zhou ZL, Yang YX, Ding J, Li YC and Miao
ZH: Triptolide: structural modifications, structure-activity
relationships, bioactivities, clinical development and mechanisms.
Nat Prod Rep. 29:457–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Han R, Rostami-Yazdi M, Gerdes S and
Mrowietz U: Triptolide in the treatment of psoriasis and other
immune-mediated inflammatory diseases. Br J Clin Pharmacol.
74:424–436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tao QS, Ren JA and Li JS: Triptolide
suppresses IL-1beta-induced chemokine and stromelysin-1 gene
expression in human colonic subepithelial myofibroblasts. Acta
Pharmacol Sin. 28:81–88. 2007.
|
|
46
|
Ren J, Tao Q, Wang X, Wang Z and Li J:
Efficacy of T2 in active Crohn’s disease: A prospective study
report. Dig Dis Sci. 52:1790–1797. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li G, et al: T2 enhances in situ level of
Foxp3 regulatory cells and modulates inflammatory cytokines in
Crohn’s disease. Int Immunopharmacol. 18:244–248. 2013. View Article : Google Scholar
|
|
48
|
Li XJ, Jiang ZZ and Zhang LY: Triptolide
Progress on research in pharmacodynamics and toxicology. J
Ethnopharmacol. 155:67–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tao X, Younger J, Fan FZ, Wang B and
Lipsky PE: Benefit of an extract of Tripterygium wilfordii Hook F
in patients with rheumatoid arthritis: a double-blind,
placebo-controlled study. Arthritis Rheum. 46:1735–1743. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wu Y, Wang Y, Zhong C, Li Y, Li X and Sun
B: The suppressive effect of triptolide on experimental autoimmune
uveoretinitis by down-regulating Th1-type response. Int
Immunopharmacol. 3:1457–1465. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yan SX and Wang Y: Inhibitory effects of
Triptolide on interferon-gamma-induced human leucocyte antigen-DR,
inter-cellular adhesion molecule-1, CD40 expression on retro-ocular
fibroblasts derived from patients with Graves’ ophthalmopathy. Clin
Experiment Ophthalmol. 34:265–271. 2006. View Article : Google Scholar : PubMed/NCBI
|
